LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease).

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Vial

MAY 20, 2024

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The two broadest categories of drug development can be separated into the preclinical and clinical research stages. over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

DrugBank

MARCH 7, 2024

As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade. adults using obesity medications by 2030, further underlining the growing significance of this sector.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies 98

Codon

NOVEMBER 3, 2024

But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030. As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers.

Vaccine 100

Vaccine Trials Therapies Treatment 100

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

Perficient: Drug Development

MARCH 14, 2024

billion by 2030. The ability to offer healthcare products and services digitally is more important than ever. In fact, the global healthcare eCommerce market is projected to reach $994.2 But a complex regulatory landscape and data privacy and security concerns are formidable obstacles.

Science 52

Science Pharmacy Marketing Production 52

Perficient: Drug Development

JANUARY 2, 2024

Billion by 2030 1 ? Being able to log in to a portal that presents condition-specific information, books, and other items for purchase is a fantastic way for providers and health systems to continue building relationships with patients and their families and become trusted advisors.

Doctors 52

Doctors Production Hospitals Marketing 52

Perficient: Drug Development

SEPTEMBER 12, 2023

trillion in potential contributions by 2030. AI technologies are already on a path to magnify gains in productivity, efficiency, and adaptability. PwC’s Global Artificial Intelligence Study predicts that businesses will see 45% of total economic gain with $15.7

Production 52

Production Government Marketing Research 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

Perficient: Drug Development

SEPTEMBER 12, 2023

Today, millennials represent 32% of the automotive market shoppers, and by 2030, that number will increase to 50%. Soon, half of all automotive shoppers are folks who have depended on computers for most of their lives. This generation lives in the digital space, so marketing must be adapted to shine and engage where the audience thrives.

Marketing 52

Marketing 52

Perficient: Drug Development

AUGUST 8, 2023

By 2030, the last of the 73 million baby boomers will cross the threshold into Medicare eligibility. Many of us have a somewhat dated view of the 65-plus population, but these folks aren’t your grandma’s grandma. Boomers may have grown up in an analog-world, but they have been steadily riding the technology wave ever since.

Production 52

Production Treatment Marketing Research 52

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. billion in 2030.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Vial

APRIL 18, 2024

from 2023 to 2030. Additionally, the ophthalmic drugs market, valued at USD 33.81 billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Our [ophthalmology CRO]( [link] team has extensive therapeutic knowledge to support all stages of ophthalmology drug development and clinical research.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Vial

FEBRUARY 15, 2024

over the forecast period (2022-2030). Focus on core competencies : By outsourcing trial management to CROs, pharmaceutical companies and research institutions can concentrate on drug development and scientific innovation, rather than administrative tasks.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Perficient: Drug Development

JULY 17, 2023

This change is one reason why it is so critical for OEMs to develop a closer relationship with consumers – not completely outsource the relationship to dealers as they have in the past. By 2030, over half of vehicle buyers will be millennials who have different expectations.

Marketing 52

Marketing Research Production 52

Vial

MARCH 27, 2024

from 2024 to 2030. The type of sponsorship must also be accounted for because academic institutions sponsoring clinical trials often have access to fewer financial resources compared with commercial sponsors, which typically have larger budgets for their drug development programs.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

NOVEMBER 5, 2020

In August 2020 , the Company issued and sold $1.250 billion aggregate principal amount of 1.750% senior unsecured notes due 2030 and $750 million aggregate principal amount of 2.800% senior unsecured notes due 2050. A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release.

Production 40

Production Trials FDA FDA Approval 40

Perficient: Drug Development

AUGUST 29, 2023

With an administration that is pushing big goals for EV adoption by 2030, and consumer demand ramping up for the latest vehicle technology, OEMs and dealers are scrambling to ensure they stay on top of the game. million 20% Biden Administration emission rules require EVs to be at 17% of sales by 2026 and 66% of sales by 2030.

Marketing 52

Marketing Production 52

Perficient: Drug Development

OCTOBER 16, 2024

trillion talent shortage projected by 2030. Addressing the Talent Shortage While fears of AI-driven job displacement dominate headlines, the real crisis looming is a $8.5

Compliance 105

Compliance Production Marketing Research 105

Perficient: Drug Development

DECEMBER 11, 2024

As the healthcare AI segment is poised to reach $187 billion by 2030, organizations must act swiftly to secure a competitive edge or risk being left behind. According to recent insights, 81% of executives expect AI to drive industry-wide efficiency gains of over 25% in the next two years.

Government 52

Government Compliance Production Science 52

PPD

JANUARY 21, 2025

However, amid this progress, the complexities of drug development have never been more apparent. Food and Drug Administration (FDA) approved 38 new molecular entities for therapeutic use, a decline from 47 in the previous year. In 2024, the U.S. The data revealed five key trends poised to shape biopharma and biotech in 2025.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

Perficient: Drug Development

JANUARY 14, 2025

trillion by 2030, growing at an impressive annual rate of 15.95% (Mordor Intelligence). trillion by 2030, at a CAGR of 28.53%. This shift isnt just a trendits a revolution. Recent research shows that the global B2B e-commerce market is expected to surge from $28.86 trillion in 2025 to $60.49 trillion in 2025 to an incredible $5.32

Marketing 52

Marketing Testimonials Production Research 52

Perficient: Drug Development

NOVEMBER 15, 2024

billion by 2030. Healthcare Trend #1: AI Disruption and Enablement Healthcare has seen a surge of interest in AI, with the market set to soar to $187.95 But the industry faces unique challenges that other sectors don’t encounter.

Regulations 64

Regulations Compliance Production Nurses 64

Perficient: Drug Development

NOVEMBER 15, 2024

billion by 2030. Healthcare Trend #1: AI Disruption and Enablement Healthcare has seen a surge of interest in AI, with the market set to soar to $187.95 But the industry faces unique challenges that other sectors don’t encounter.

Regulations 52

Regulations Compliance Production Nurses 52